

Special Issue

SARS-CoV-2 Vaccination in Transplant Recipients

Message from the Guest Editors

Recipients of solid organ transplants are at a high risk of developing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated complications. The introduction of targeted vaccines has mitigated the risk of developing infection, albeit with a continued suboptimal response in comparison to the general population. This suboptimal response is mostly attributable to the use of maintenance immunosuppression to prevent organ rejection. This issue will cover the following pertinent aspects of the SARS-CoV-2 vaccine in recipients of solid organ transplantation:

1. Track the arc of development of the SARS-CoV-2 vaccines and their use in recipients of solid organ transplants;
2. Review vaccine response in transplant recipients focused on each type of solid organ transplantation;
3. Methods of monitoring immune response to vaccines;
4. Measures to reduce the risk of infection in patients with an absent/reduced response to vaccines.

Guest Editors

Dr. Sam Kant

Johns Hopkins School of Medicine, Baltimore, MD, USA

Prof. Dr. Daniel Brennan

Medical Director, Comprehensive Transplant Center, The Johns Hopkins Hospital, Baltimore, MD, USA

Deadline for manuscript submissions

closed (30 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/138046

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).